Research Article
BibTex RIS Cite

Year 2025, Volume: 46 Issue: 1, 22 - 26, 25.03.2025

Sibel Yiğit Alaşalvar , Elif Şahin , Eşref Edip Keha

https://doi.org/10.17776/csj.1549477
https://izlik.org/JA98SY76WF

Abstract

References

  • [1] Supuran C. T., Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection, Expert Opinion on Investigational Drugs, 33(5) (2024) 523–532.
  • [2] Bayram E., Senturk M., Kufrevioglu O. I., Supuran C. T., In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II, Bioorganic & Medicinal Chemistry, 16(20) (2008) 9101–9105.
  • [3] Alver A., Menteşe A., Karahan S. C., Erem C., Keha E. E., Arikan M. K., Eminağaoğlu M. S., Deger O., Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 115(5) (2007) 287–291.
  • [4] Nishimori I., Onishi S., Takeuchi H., Supuran C. T., The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets, Current Pharmaceutical Design, 14(7) (2008) 622–630.
  • [5] Janeway C.A., Travers P., Walport M., Immunobiology: The Immune System in Health and Disease, 5th ed. New York: Garland Science; 2001.
  • [6] Nista E. C., De Lucia S. S., Manilla V., Schepis T., Pellegrino A., Ojetti V., Pignataro G., Zileri Dal Verme L., Franceschi F., Gasbarrini A., Candelli M., Autoimmune Pancreatitis: From Pathogenesis to Treatment, International Journal of Molecular Sciences, 23(20) (2022) 12667.
  • [7] Inagaki Y., Jinno-Yoshida Y., Hamasaki Y., Ueki H., A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren's syndrome, Journal of Dermatological Science, 2(3) (1991) 147–154.
  • [8] Yokode M., Shiokawa M., Kodama Y., Review of Diagnostic Biomarkers in Autoimmune Pancreatitis: Where Are We Now?, Diagnostics (Basel, Switzerland), 11(5) (2021) 770.
  • [9] Goyal S., Sakhuja P., Autoimmune pancreatitis: Current perspectives. Indian Journal of Pathology & Microbiology, 64 (2021), S149–S159.
  • [10] Aparisi L., Farre A., Gomez-Cambronero L., Martinez J., De Las Heras G., Corts J., Navarro S., Mora J., Lopez-Hoyos M., Sabater L., Ferrandez A., Bautista D., Perez-Mateo M., Mery S., Sastre J., Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis, Gut, 54(5) (2005) 703–709.
  • [11] Guarneri F., Guarneri C., Benvenga S., Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?, Journal of Cellular and Molecular Medicine, 9(3) (2005) 741–744.
  • [12] Iyer R., Barrese A. A., 3rd, Parakh, S., Parker, C. N., Tripp, B. C., Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds, Journal of Biomolecular Screening, 11(7) (2006) 782–791.
  • [13] Comay D., Cauch-Dudek K., Hemphill D., Diamandis E., Wanless I., Heathcote E. J., Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?, Digestive Diseases and Sciences, 45(10) (2000) 2018–2021.
  • [14] Sharker M. R., Sukhan Z. P., Sumi K. R., Choi S. K., Choi K. S., Kho K. H., Molecular Characterization of Carbonic Anhydrase II (CA II) and Its Potential Involvement in Regulating Shell Formation in the Pacific Abalone, Haliotis discus hannai. Frontiers in Molecular Biosciences, 8 (2021) 669235.
  • [15] Supuran C. T., Structure and function of carbonic anhydrases. The Biochemical Journal, 473(14) (2016) 2023–2032.
  • [16] Hosoda H., Okawa-Takatsuji M., Tanaka A., Uwatoko S., Aotsuka S., Hasimoto N., Ozaki Y., Ikeda Y., Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. Clinica Chimica Acta; International Journal Of Clinical Chemistry, 342(1-2) (2004) 71–81.

Investigation of Anti-CA II Antibodies in The Sera of Helicobacter Pylori Infected Patients

Year 2025, Volume: 46 Issue: 1, 22 - 26, 25.03.2025

Sibel Yiğit Alaşalvar , Elif Şahin , Eşref Edip Keha

https://doi.org/10.17776/csj.1549477
https://izlik.org/JA98SY76WF

Abstract

It has been postulated that there may be a correlation between gastric infection caused by Helicobacter pylori (H. Pylori) and autoimmune pancreatitis (AIP). An increase in carbonic anhydrase II (CA II) autoantibodies was found in the sera of patients with AIP and it was suggested that measurement of these autoantibodies could be used in the diagnosis of AIP. In this study, the levels of CA II autoantibodies have been determined in the sera of the patients with H. pylori-infected gastritis and gastric ulcer. Anti-CA II antibody levels in the sera of these individuals were measured by ELISA method. There were significant differences between the control group and the H. pylori-infected gastric ulcer group and the gastritis group. When the H. pylori-infected and non-infected gastric ulcer and gastritis groups were compared, it became apparent that there were notable differences. The results indicated that the CA II antibodies in the sera of the H. pylori-infected patients were present at a rate of 8.3%. This led to the conclusion that CA II antibodies may not be a reliable marker for H. pylori infection. However, the investigation did demonstrate a clear increase in the levels of CA II antibodies for H. pylori-infected patients.

Keywords

Helicobacter pylori anti-CA II autoimmune disease ELISA

References

  • [1] Supuran C. T., Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection, Expert Opinion on Investigational Drugs, 33(5) (2024) 523–532.
  • [2] Bayram E., Senturk M., Kufrevioglu O. I., Supuran C. T., In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II, Bioorganic & Medicinal Chemistry, 16(20) (2008) 9101–9105.
  • [3] Alver A., Menteşe A., Karahan S. C., Erem C., Keha E. E., Arikan M. K., Eminağaoğlu M. S., Deger O., Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 115(5) (2007) 287–291.
  • [4] Nishimori I., Onishi S., Takeuchi H., Supuran C. T., The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets, Current Pharmaceutical Design, 14(7) (2008) 622–630.
  • [5] Janeway C.A., Travers P., Walport M., Immunobiology: The Immune System in Health and Disease, 5th ed. New York: Garland Science; 2001.
  • [6] Nista E. C., De Lucia S. S., Manilla V., Schepis T., Pellegrino A., Ojetti V., Pignataro G., Zileri Dal Verme L., Franceschi F., Gasbarrini A., Candelli M., Autoimmune Pancreatitis: From Pathogenesis to Treatment, International Journal of Molecular Sciences, 23(20) (2022) 12667.
  • [7] Inagaki Y., Jinno-Yoshida Y., Hamasaki Y., Ueki H., A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren's syndrome, Journal of Dermatological Science, 2(3) (1991) 147–154.
  • [8] Yokode M., Shiokawa M., Kodama Y., Review of Diagnostic Biomarkers in Autoimmune Pancreatitis: Where Are We Now?, Diagnostics (Basel, Switzerland), 11(5) (2021) 770.
  • [9] Goyal S., Sakhuja P., Autoimmune pancreatitis: Current perspectives. Indian Journal of Pathology & Microbiology, 64 (2021), S149–S159.
  • [10] Aparisi L., Farre A., Gomez-Cambronero L., Martinez J., De Las Heras G., Corts J., Navarro S., Mora J., Lopez-Hoyos M., Sabater L., Ferrandez A., Bautista D., Perez-Mateo M., Mery S., Sastre J., Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis, Gut, 54(5) (2005) 703–709.
  • [11] Guarneri F., Guarneri C., Benvenga S., Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?, Journal of Cellular and Molecular Medicine, 9(3) (2005) 741–744.
  • [12] Iyer R., Barrese A. A., 3rd, Parakh, S., Parker, C. N., Tripp, B. C., Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds, Journal of Biomolecular Screening, 11(7) (2006) 782–791.
  • [13] Comay D., Cauch-Dudek K., Hemphill D., Diamandis E., Wanless I., Heathcote E. J., Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?, Digestive Diseases and Sciences, 45(10) (2000) 2018–2021.
  • [14] Sharker M. R., Sukhan Z. P., Sumi K. R., Choi S. K., Choi K. S., Kho K. H., Molecular Characterization of Carbonic Anhydrase II (CA II) and Its Potential Involvement in Regulating Shell Formation in the Pacific Abalone, Haliotis discus hannai. Frontiers in Molecular Biosciences, 8 (2021) 669235.
  • [15] Supuran C. T., Structure and function of carbonic anhydrases. The Biochemical Journal, 473(14) (2016) 2023–2032.
  • [16] Hosoda H., Okawa-Takatsuji M., Tanaka A., Uwatoko S., Aotsuka S., Hasimoto N., Ozaki Y., Ikeda Y., Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. Clinica Chimica Acta; International Journal Of Clinical Chemistry, 342(1-2) (2004) 71–81.
There are 16 citations in total.

Details

Primary Language English
Subjects Microbiology (Other), Medical Biochemistry - Proteins, Peptides and Proteomics
Journal Section Research Article
Authors

Sibel Yiğit Alaşalvar 0000-0003-4472-7554

Elif Şahin 0000-0001-5864-9548

Eşref Edip Keha 0000-0002-2271-5811

Submission Date September 17, 2024
Acceptance Date February 12, 2025
Publication Date March 25, 2025
DOI https://doi.org/10.17776/csj.1549477
IZ https://izlik.org/JA98SY76WF
Published in Issue Year 2025 Volume: 46 Issue: 1

Cite

APA Yiğit Alaşalvar, S., Şahin, E., & Keha, E. E. (2025). Investigation of Anti-CA II Antibodies in The Sera of Helicobacter Pylori Infected Patients. Cumhuriyet Science Journal, 46(1), 22-26. https://doi.org/10.17776/csj.1549477

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December